The Personal Discovery Process (PDP) provides individuals with treatment-driven research on an unprecedented scale. It is effectively a massive clinical trial for a single patient. We engineer the genetic complexity of each patient's unique tumour network into an army of 400,000 fruit fly "avatars". Using robotics, we evaluate up to 2,000 FDA approved drugs including non-cancer drugs, to identify drug combinations that are efficacious in the individual's avatar population.

The Icahn School of Medicine at Mount Sinai developed the PDP methodology over years of clinical research. They found that real-world patient tumours are made resistant to single-drug treatments by mutations in several genes, including genes not previously associated with cancer. Such resistant tumours can, however, be effectively addressed with novel combinations of FDA approved drugs. The most effective combinations almost always include non-cancer drugs. The Personal Discovery Process methods are licensed exclusively to My Personal Therapeutics and Medicision is proud to be their exclusive partner for Australia and New Zealand.